Core Viewpoint - The highest level of medical intelligence is considered to be L4, which emphasizes "human-machine collaboration" rather than a fully automated medical environment [1][20]. Industry Insights - The global medical AI market is projected to exceed $100 billion by 2030, with medical imaging AI being one of the fastest-growing segments [2]. - The company has been a pioneer in systematically laying out ultrasound AI since 2016, adopting a "device + AI" strategy that integrates AI deeply into medical devices [3][4]. Technological Development - The company focuses on three core advantages of its "device + AI" approach: implementation advantage, integration advantage, and performance advantage [4]. - The "Fengyan S-Fetus" technology, which integrates ultrasound technology with AI, has achieved significant milestones, including obtaining the first domestic prenatal ultrasound AI medical device certification [4][11]. Data and Model Training - High-quality, well-distributed data is crucial for the effective application of AI in clinical settings [5][15][16]. - The company collaborates with various medical institutions to build a clinical data cooperation system, ensuring compliance with ethical standards and data privacy [16]. Future Directions - The company aims to achieve a "fully intelligent machine" concept, where AI drives the entire clinical process, covering major application areas such as gynecology, obstetrics, cardiology, and more [21]. - The integration of visual models with large language models is being explored to enhance diagnostic capabilities [17]. Regulatory and Policy Considerations - The registration process for AI products is more stringent than for traditional medical devices, emphasizing the need for rigorous clinical trials and data integrity [12][11]. - There is a call for improved regulatory frameworks to support the integration of AI in healthcare, ensuring that AI can be effectively utilized while maintaining human oversight [22][23].

Summary of the Incentive Plan Announcement Core Viewpoint The announcement details the implementation of the 2025 Restricted Stock and Stock Option Incentive Plan by Shenzhen Kaili Biomedical Technology Co., Ltd., which includes the granting of restricted stocks and stock options to 405 incentive objects, aimed at motivating key personnel and enhancing company performance. Group 1: Incentive Plan Overview - The company has approved the granting of 1.914 million shares of restricted stock and 3.9678 million stock options to 405 incentive objects, including directors, senior management, and key technical personnel [1][21]. - The grant date for the restricted stock and stock options is set for October 16, 2025, with a grant price of 15.93 yuan per share for restricted stock and an exercise price of 31.86 yuan per option [2][17]. Group 2: Performance Assessment Requirements - The performance assessment for the incentive plan will be conducted annually from 2025 to 2028, with specific targets set for each fiscal year [5][6]. - If the company fails to meet the performance targets in any given year, the corresponding restricted stocks and stock options for that year will not vest or be exercisable, and will be forfeited [6][10]. Group 3: Decision-Making Process - The plan underwent a thorough decision-making process, including multiple board meetings and approvals from the remuneration and assessment committee, ensuring compliance with relevant laws and regulations [11][13][22]. - The company conducted a self-examination regarding insider trading by participants in the incentive plan, confirming no violations occurred in the six months prior to the grant date [24]. Group 4: Financial Implications - The funds raised through this incentive plan will be used to supplement the company's working capital [25]. - The company anticipates that the costs associated with the incentive plan will have a minor impact on net profits, while the potential positive effects on performance and management motivation are expected to outweigh these costs [30].

Core Points - The company announced the convening of the 10th meeting of the 4th Board of Directors and the 10th meeting of the 4th Supervisory Board on October 16, 2025 [2] - The meetings approved the adjustment of the list of incentive objects for the 2025 restricted stock and stock option incentive plan [2] - The company will grant 1.914 million shares of the second category of restricted stock to 99 incentive objects and 3.9678 million stock options to 306 incentive objects [2]

Core Points - The company announced an adjustment to its 2025 restricted stock and stock option incentive plan due to one participant voluntarily giving up their participation [2] - The number of participants in the incentive plan has been reduced from 406 to 405, while the total amount of equity granted remains unchanged [2] - The adjustment was made under the authorization of the company's first extraordinary general meeting of 2025 [2]

Group 1 - The company, Kaili Medical, held its 11th meeting of the 4th board of directors on October 16, 2025, in Shenzhen, where it reviewed proposals related to the grant of restricted stocks and stock options under the 2025 incentive plan [1] - The meeting took place at the Kaili Medical Building located at No. 368, Optoelectronic North Road, Guangming District, Shenzhen [1]

本次会议应出席董事 7 人，实际出席董事 7 人，会议由董事长陈志强先生主 持，符合《公司章程》规定的法定人数，会议的召集、召开符合《公司法》和《公 司章程》的有关规定。 证券代码：300633 证券简称：开立医疗 公告编号：2025-041 深圳开立生物医疗科技股份有限公司 第四届董事会第十一次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 2025 年 10 月 16 日，深圳开立生物医疗科技股份有限公司（以下简称"公 司"）第四届董事会第十一次会议以现场和通讯表决相结合的方式在深圳市光明 区光电北路 368 号开立医疗大厦一楼会议室召开。本次会议已于 2025 年 10 月 13 日以电话、电子邮件等方式通知全体董事。 二、董事会会议审议情况 经与会董事投票表决，审议通过了如下决议： 1、审议通过《关于调整 2025 年限制性股票与股票期权激励计划激励对象 名单相关事项的议案》 公司《2025 年限制性股票与股票期权激励计划（草案）》（以下简称"《激励 计划》"或"本次激励计划"）所确定的 406 名激励对象中，1 ...

证券代码：300633 证券简称：开立医疗 公告编号：2025-042 深圳开立生物医疗科技股份有限公司 第四届监事会第十次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 2025 年 10 月 16 日，深圳开立生物医疗科技股份限公司（以下简称"公司"） 第四届监事会第十次会议在深圳市光明区光电北路 368 号开立医疗大厦一楼会 议室召开。本次会议由监事会主席陈欣主持。应出席监事 3 名，实际出席监事 3 名。符合《公司章程》规定的法定人数，本次监事会会议决议合法有效。 二、监事会会议审议情况 经与会监事审议表决，一致通过了如下决议： 2、审议通过《关于向 2025 年限制性股票与股票期权激励计划激励对象授 予限制性股票与股票期权的议案》 监事会对本次激励计划确定的授予激励对象是否符合授予条件进行核实后， 监事会认为： 1、本次激励计划授予的激励对象均为公司 2025 年第一次临时股东大会审议 通过的公司《激励计划》中确定的激励对象中的人员。 2、不存在《管理办法》第八条所述不得成为激励对象的下列情形： （1）最近 12 ...

证券代码：300633 证券简称：开立医疗 公告编号：2025-043 深圳开立生物医疗科技股份有限公司 关于调整 2025 年限制性股票与股票期权激励计划激励对象名单 相关事项的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 深圳开立生物医疗科技股份有限公司（以下简称"公司"）于 2025 年 10 月 16 日召开第四届董事会第十一次会议、第四届监事会第十次会议，审议通过 了《关于调整 2025 年限制性股票与股票期权激励计划激励对象名单相关事项的 议案》，现将有关事项说明如下： 一、已履行的相关审批程序 （三）公司于 2025 年 9 月 6 日至 2025 年 9 月 15 日在公司内部公示了本次 激励计划激励对象的姓名和职务。在公示的期限内，未收到任何组织或个人提 出异议或不良反映。公司于 2025 年 9 月 16 日披露了《董事会薪酬与考核委员 会关于公司 2025 年限制性股票与股票期权激励计划激励对象名单的核查意见及 公示情况说明》。 （四）公司对本次激励计划内幕信息知情人及激励对象在激励计划（草案） 公开披露前 6 个月内，即 202 ...

法律意见书 二〇二五年十月 北京 • 上海 • 深圳 • 广州 • 武汉 • 成都 • 重庆 • 青岛 • 杭州 • 南京 • 海口 • 东京 • 香港 • 伦敦 • 纽约 • 洛杉矶 • 旧金山 • 阿拉木图 Beijing • Shanghai • Shenzhen • Guangzhou • Wuhan • Chengdu • Chongqing • Qingdao • Hangzhou • Nanjing • Haikou • Tokyo • Hong Kong • London • New York • Los Angeles • San Francisco • Almaty | 一、 | 本次调整及本次授予的批准和授权 6 | | --- | --- | | 二、 | 本次调整的具体内容 8 | | 三、 | 本次授予的具体内容 8 | | 四、 | 结论意见 11 | 法律意见书 北京市中伦（深圳）律师事务所 关于深圳开立生物医疗科技股份有限公司 2025年限制性股票与股票期权激励计划 调整及授予相关事项的 释义 在本法律意见书中，除非另有说明，以下简称或用语具有如下含义： | 公司/开立医疗 ...

深圳开立生物医疗科技股份有限公司（以下简称"公司"）第四届监事会第 十次会议于 2025 年 10 月 16 日在公司会议室召开，审议通过了《关于调整 2025 年限制性股票与股票期权激励计划激励对象名单相关事项的议案》、《关于向 2025 年限制性股票与股票期权激励计划激励对象授予限制性股票与股票期权的 议案》。公司监事会根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中 华人民共和国证券法》（以下简称"《证券法》"）、《上市公司股权激励管理办法》 （以下简称"《管理办法》"）、《深圳证券交易所创业板股票上市规则》（以下简称 "《上市规则》"）等相关法律、法规和规范性文件以及公司《2025 年限制性股票 与股票期权激励计划（草案）》（以下简称"《激励计划》"或"本次激励计划"）、 《公司章程》的有关规定，对公司 2025 年限制性股票与股票期权激励计划激励对 象名单（授予日）进行审核，发表核查意见如下： （一）鉴于公司《2025 年限制性股票与股票期权激励计划（草案）》（以下简 称"《激励计划》"或"本次激励计划"）确定的激励对象名单中，1 名激励对象 因个人原因自愿放弃参与本次激励计划，根据公司 ...